ID 93

Drug Profile

ID 93

Alternative Names: ID 93/AP10-602; ID-93/GLA-SE; ID93 + AP10-602; ID93 + GLA-SE; Tuberculosis vaccine adjuvanted - Aeras/Infectious Disease Research Institute; Tuberculosis vaccine recombinant Mycobacterium tuberculosis protein ID93/adjuvant GLA-SE - Aeras/IDRI

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Infectious Disease Research Institute
  • Developer Aeras; Infectious Disease Research Institute
  • Class Recombinant fusion proteins; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Tuberculosis(Prevention) in USA (IM, Injection)
  • 17 Sep 2015 The Infectious Disease Research Institute plans a phase II trial for Tuberculosis
  • 31 Jul 2015 National Institute of Allergy and Infectious Diseases plans a phase I trial in Tuberculosis (Prevention) in USA (NCT02508376)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top